ERS Genomics Archives

Expert Advice 16 Feb 2023

Five things you need to know about using CRISPR/Cas9 commercially

By Michael Arciero, vice president of intellectual property and corporate development, ERS Genomics CRISPR/Cas9 gene editing technology is a patented invention, so any commercial use requires a license. Despite the confusion caused by several high-profile patent interference cases, the patent landscape for CRISPR/Cas9 is clearer than you may think. Here are the 5 key facts […]

February 16, 2023 - 6 minutesmins - By External Contributor

Best in Biotech 21 May 2019

The Top 20 Women in Leading Biotech Roles in Europe

The biotech industry has often been criticized for its lack of gender diversity. While there is still a long way to go to achieve ideal levels of equality, there are more and more women filling leading roles in companies across Europe. Here are 20 women making an impact in the European biotech industry. Diversity comes […]

May 21, 2019 - 12 minutesmins - By Jonathan Smith

News and Trends 1 Mar 2018

Doudna and Charpentier Get Second CRISPR Patent in Europe

Just a month after the European Patent Office revoked a CRISPR patent from the competitors of Doudna and Charpentier, they have been granted a second patent that covers a new form of the popular gene editing tool. The European Patent Office has granted CRISPR co-inventor Emmanuelle Charpentier, together with the University of California and the University […]

March 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Jan 2018

The European Patent Office Revokes the Broad Institute‘s CRISPR Patents

The Broad Institute has been dealt a big blow in its battle for CRISPR/Cas9 intellectual property, with the European Patent Office revoking one of its patents. CRISPR/Cas9 has been hailed as the ‘scientific discovery of the century’ due to its capacity to modify the genome for the treatment of genetic diseases. The Broad Institute, set up by MIT […]

January 19, 2018 - 3 minutesmins - By Alex Dale

Infographics 21 Jun 2017

Check Out these 42 European SynBio Startups Reimagining the Industry

Synthetic biology, or synbio for short, is rapidly infiltrating multiple fields. From bioplastics to food technology and healthcare, these are the startups in Europe that are expanding the frontiers of what synbio can do to improve our lives in many different ways. In the not-so-distant future, synthetic biology could bring us anything from spider silk […]

June 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández

European Patent Office CRISPR Decision 1

News and Trends 28 Mar 2017

Europe Turns the Tables in the CRISPR Patent Battle

ERS Genomics has announced that the EPO intends to grant a patent with broad claims covering the use of CRISPR to Emmanuelle Charpentier. ERS Genomics has announced that the European Patent Office (EPO) will grant its founder, Emmanuelle Charpentier as well as the University of Vienna and University of California, Berkeley, a patent covering the broad use of CRISPR-Cas9 […]

March 28, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 8 Nov 2016

Swiss SynBio adds CRISPR to its Toolkit for new Specialty Chemicals

Evolva is licensing the CRISPR patents of Emmanuelle Charpentier, in a deal with holding company ERS Genomics. This will grant access to the wonder gene-editing technology for one of the most important players in European SynBio. Headquartered in Switzerland, Evolva develops new ways to obtain ingredients and specialty chemicals with brewing and engineered microorganisms. Its […]

November 8, 2016 - 2 minutesmins - By Denise Neves Gameiro

crispr charpentier ers genomics bayer blsc

News and Trends 18 May 2016

Bayer claims CRISPR Patents for Gene-Editing Agreements

Bayer has signed a patent license agreement with ERS Genomics, that controls patents for the CRISPR-Cas9 system – a breakthrough gene-editing technology. Bayer Lifescience Center (BLSC) is the innovation division of German Giant Bayer, which aims to address challenges in the pharmaceutical and agro-industry. Its strategy is to establish collaborations with innovative Biotechs, and create a […]

May 18, 2016 - 2 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us